

---

## ...BIBLIOGRAPHY...

- American Diabetes Association Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2000;23(suppl 1):S4-S19.
- American Diabetes Association Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Position Statement: Standards of medical care for patients with diabetes mellitus. *Diabetes Care* 2000; 23(suppl 1):S32-S42.
- American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. *Diabetes Care* 1998;21:296-308.
- American Diabetes Association. Management of dyslipidemia in adults with diabetes. *Diabetes Care* 1999;22(suppl 1):S56-S59.
- American Diabetes Association. Position Statement: Diabetic Retinopathy. *Diabetes Care* 1999;22(suppl 1):S70-S73.
- Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult U.S. population: Data from the Health Examination Surveys, 1960-1991. *Hypertension* 1995;26:60-69.
- Campbell LK, White JR, Campbell RK. Acarbose: Its role in the treatment of diabetes mellitus. *Ann Pharmacother* 1996;30:1255-1262.
- CDC Diabetes in Managed Care Work Group. Exploring and expanding the research agenda for diabetes in managed care. *Diabetes Care* 1999;22:1734-1738.
- Centers for Disease Control and Prevention. *Diabetes Surveillance*, 1997. Atlanta, GA: US Department of Health and Human Services;1997:15-36.
- Centers for Disease Control. Diabetes preventive-care practices in managed-care organizations—Rhode Island, 1995-1996. *MMWR Morb Mortal Wkly Rep* 1999;48:958-961.
- Collaborative overview of randomized trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. *BMJ* 1994;308:81-106.
- Cowie CC, Eberhardt MS. Physical and metabolic characteristics of persons with diabetes. In: Harris MI, ed. *Diabetes America*. Bethesda, MD: National Institutes of Health; 1995. NIH publication 95-1468.
- DAIS Project Group. The Diabetes Atherosclerosis Intervention Study (DAIS): A study conducted in cooperation with the World Health Organization. *Diabetologia* 1996;39:1655-1661.
- DCCT: The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-986.
- DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 1999;131:281-303.
- Diabetes Research Working Group. *Conquering Diabetes: A Strategic Plan for the 21st Century*. Bethesda, MD: National Institutes of Health;1999:2. NIH publication 99-4398.
- Domurat ES. Diabetes managed care and clinical outcomes. *Am J Manag Care* 1999;5:1299-1307.
- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. *JAMA* 1998;279:1615-1622.
- Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. *BMJ* 1998;317:713-720.
- Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. *Am J Med* 1998;105(suppl 1A):77S-82S.
- Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. *Circulation* 1996;98:2513-2519.
- Goldberg RB. Cardiovascular disease in diabetic patients. *Med Clin North Am* 2000;84:1-93.
- Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation* 2000;101:477-484.
- Grundy SM. Cholesterol management in the era of managed care. *Am J Cardiol* 2000;85:3A-9A.

---

...BIBLIOGRAPHY...

- Grundy SM. Hypertriglyceridemia, atherogenic hyperlipidemia and the metabolic syndrome. *Am J Cardiol* 1998;81:18B-25B.
- Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998;339:229-234.
- Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. *Am J Med* 1997;103:152-162.
- Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA* 1990;263:2893-2898.
- Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. *Diabetes Care* 1998; 21:518-524.
- Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE Study and MICRO-HOPE substudy. *Lancet* 2000;355:253-259.
- Hebert LA, Bain RP, Verme D, et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. *Kidney Int* 1994;46:1688-1693.
- Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. *Circulation* 1996;93: 1809-1817.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 1998;352:837-853.
- Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among U.S. adults: The National Health and Nutrition Examination Surveys. *JAMA* 1993;269:3002-3008.
- Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham Study. *JAMA* 1979;241: 2035-2038.
- Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. *Diabetes Care* 1995;18:258-268.
- Klip A, Leiter LA. Cellular mechanism of action of metformin. *Diabetes Care* 1990;13:696-704.
- Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. *Circulation* 1992; 85:37-45.
- Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. *N Engl J Med* 1994;331:1188-1193.
- Olefsky JM. In: Porte D Jr, Sherwin RS, eds. *Ellenberg & Rifkin's Diabetes Mellitus*, 5th ed. Stamford, CT: Appleton & Lange; 1997.
- Pell S, Fayerweather WE. Trends in the incidence of myocardial infarction and in associated mortality and morbidity in a large employed population, 1957-1983. *N Engl J Med* 1985;312:1005-1011.
- Perseghin G, Price TB, Pedersen KF, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. *N Engl J Med* 1996;335:1357-1362.
- Peters AL, Thompson R, Ryan D. Glycohemoglobin assessment program (GAP): What is the level of diabetes management in primary care? *Diabetes* 1999;48(suppl 1):A194.
- Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care* 1997;20:614-620.
- Ramsey SD, Newton K, Blough D, et al. Patient-level estimates of the cost of complications in diabetes in a managed-care population. *Pharmacoeconomics* 1999;16:285-295.
- Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperlipidemia in individuals with small, dense low density lipoprotein particles. *J Clin Invest* 1993;92:1541-1546.
- Reaven GM, Hollenbeck CB, Chen YD. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. *Diabetologia* 1989;32:52-55.

---

...BIBLIOGRAPHY...

- Rubin RJ, Dietrich KA, Hawk AD. Clinical and economic impact of implementing a comprehensive diabetes management program in managed care. *J Clin Endocrinol Metab* 1998;83:2635-2642.
- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1999;341:410-418.
- Saudek CD. When does diabetes start? *JAMA* 1990;263:2934.
- Schmitz A, Vaeth M. Microalbuminuria: A major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. *Diabet Med* 1988;5:126-134.
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993;16:434-444.
- Streja DA, Rabkin SW. Factors associated with implementation of preventive care measures in patients with diabetes mellitus. *Arch Intern Med* 1999;159:294-302.
- The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-986.
- The Diabetes Prevention Program Research Group. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. *Diabetes Care* 1999;22:623-634.
- Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. *BMJ* 1998;316:823-828.
- UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). *BMJ* 1998;317:703-713.
- UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39). *BMJ* 1998;317:713-720.
- Uusitupa M, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin dependent diabetic and non-diabetic subjects. *Circulation* 1990;82:27-36.
- Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN. Low cardiorespiratory fitness and physical activity as predictors of mortality in men with type 2 diabetes. *Ann Intern Med* 2000;132:605-611.
- Wilson PW, Kannel WB, Anderson KM. Lipids, glucose tolerance and vascular disease: The Framingham Study. *Monogr Atheroscler* 1985;13:1-11.
- Wing RR, Koeske R, Epstein LH, Norwalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. *Arch Intern Med* 1987;147:1749-1753.
- Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, ed. *Diabetes in America*, 2nd edition. Bethesda, MD: National Institutes of Health; 1995. NIH publication 95-1468.
- Yallow RS, Berson SA. Assay of plasma insulin in human subjects by immunological methods. *Nature* 1959;184:1648.